Gideon Walter
Managing Director & Senior Partner
New Jersey
Gideon Walter leads the North America Operations practice of Boston Consulting Group. He is a member of BCG’s Health Care, Operations, Consumer, and Marketing, Sales & Pricing practices. He is also the firm’s supply chain topic leader for North America.
Since joining BCG in 2005, Gideon has focused on large-scale transformations, primarily in strategy, operations, supply chain, and organization and culture. He has led global supply chain transformations and reorganizations in biopharma, created operational-excellence programs for manufacturing in pharmaceuticals, and driven supply chain optimization in fast-moving consumer goods.
Gideon has also worked with clients across a wide range of industries on integrated supply-planning programs; strategy and implementation of enterprise resource planning; standardization of business processes; and supply chain, distribution, and logistics.
Before joining BCG, Gideon was a vice president and general-merchandise manager for Delia's, a US multichannel retailer.
Companies seeking to reduce their environmental footprint should focus on one element of their operations in particular—their global supply chains.
The COVID-19 pandemic provides some valuable lessons on how to mitigate potential risks in the future. Hint: technology is only part of the answer.
Companies that master the challenges of data integration and advanced analytics can realize the promised benefits of end-to-end supply chain coordination
Changes to standard operating procedures won’t be enough. To avoid costly drug shortages, biopharma companies need a comprehensive strategy for improving supply chain reliability.
Some companies are achieving dramatic returns on their digital investments, thanks to much more powerful technologies—and a set of key strategies.
BCG has identified a new approach to help pharmaceutical companies improve the robustness of their manufacturing processes, a shift that could save the industry $25 billion.
Biopharmaceutical manufacturing quality levels remain below those of other industries—making it critical for biopharma companies to up the effectiveness and efficiency of their quality efforts.
Successful transformation requires more than technical improvements to drive value throughout the business—people change is paramount.
